Full Year 2023 Ajanta Pharma Ltd Earnings Call Transcript
Ladies and gentlemen, good day, and welcome to the Ajanta Pharma Q4 FY 2023 earnings conference call. (Operator Instructions) Please note that this conference is being recorded. I now hand the conference over to Mr. Yogesh Agrawal, Managing Director of Ajanta Pharma Limited. Thank you, and over to you, sir.
Thank you. Good evening. And welcome to all of you. With me, I have Mr. Rajesh Agrawal, our Joint Managing Director, Mr. Arvind Agrawal, CFO, and Rajeev Agrawal, our AVP, Finance and Investor Relation. I hope our results are already there with you. We continued our growth in branded generic business, which is our mainstay and also outperformed the market going ahead.
However, the year saw severe pressure on the margin with EBITDA going down sharply from 28% last year to 21% this year. This was due to the factors beyond our control, like increasing material prices, (inaudible) price erosion, increasing stake costs, et cetera. We have taken effective steps to contain this impact and are confident of regaining
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
